Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Argus Health
Express Scripts
Harvard Business School
Teva
Farmers Insurance
Accenture
Merck
Medtronic
UBS

Generated: January 21, 2018

DrugPatentWatch Database Preview

EMBEDA Drug Profile

« Back to Dashboard

Which patents cover Embeda, and when can generic versions of Embeda launch?

Embeda is a drug marketed by Alpharma Pharms and is included in one NDA. There are nine patents protecting this drug and three Paragraph IV challenges.

This drug has sixty-one patent family members in twenty-two countries.

The generic ingredient in EMBEDA is morphine sulfate; naltrexone hydrochloride. There are twenty-three drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the morphine sulfate; naltrexone hydrochloride profile page.
Summary for EMBEDA
International Patents:61
US Patents:9
Applicants:1
NDAs:1
Suppliers / Packagers: 2
Clinical Trials: 7
Formulation / Manufacturing:see details
Drug Prices:see details
DailyMed Link:EMBEDA at DailyMed
Drug patent expirations by year for EMBEDA
Pharmacology for EMBEDA

US Patents and Regulatory Information for EMBEDA

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Alpharma Pharms EMBEDA morphine sulfate; naltrexone hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 022321-005 Aug 13, 2009 RX Yes No ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Alpharma Pharms EMBEDA morphine sulfate; naltrexone hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 022321-004 Aug 13, 2009 RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Alpharma Pharms EMBEDA morphine sulfate; naltrexone hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 022321-006 Aug 13, 2009 RX Yes No ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Alpharma Pharms EMBEDA morphine sulfate; naltrexone hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 022321-005 Aug 13, 2009 RX Yes No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Alpharma Pharms EMBEDA morphine sulfate; naltrexone hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 022321-006 Aug 13, 2009 RX Yes No ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Alpharma Pharms EMBEDA morphine sulfate; naltrexone hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 022321-004 Aug 13, 2009 RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Alpharma Pharms EMBEDA morphine sulfate; naltrexone hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 022321-004 Aug 13, 2009 RX Yes Yes ➤ Subscribe ➤ Subscribe ➤ Subscribe
Alpharma Pharms EMBEDA morphine sulfate; naltrexone hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 022321-004 Aug 13, 2009 RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Alpharma Pharms EMBEDA morphine sulfate; naltrexone hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 022321-001 Aug 13, 2009 RX Yes No ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Alpharma Pharms EMBEDA morphine sulfate; naltrexone hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 022321-002 Aug 13, 2009 RX Yes No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Expired US Patents for EMBEDA

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Alpharma Pharms EMBEDA morphine sulfate; naltrexone hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 022321-005 Aug 13, 2009 ➤ Subscribe ➤ Subscribe
Alpharma Pharms EMBEDA morphine sulfate; naltrexone hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 022321-002 Aug 13, 2009 ➤ Subscribe ➤ Subscribe
Alpharma Pharms EMBEDA morphine sulfate; naltrexone hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 022321-001 Aug 13, 2009 ➤ Subscribe ➤ Subscribe
Alpharma Pharms EMBEDA morphine sulfate; naltrexone hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 022321-002 Aug 13, 2009 ➤ Subscribe ➤ Subscribe
Alpharma Pharms EMBEDA morphine sulfate; naltrexone hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 022321-006 Aug 13, 2009 ➤ Subscribe ➤ Subscribe
Alpharma Pharms EMBEDA morphine sulfate; naltrexone hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 022321-003 Aug 13, 2009 ➤ Subscribe ➤ Subscribe
Alpharma Pharms EMBEDA morphine sulfate; naltrexone hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 022321-001 Aug 13, 2009 ➤ Subscribe ➤ Subscribe
Alpharma Pharms EMBEDA morphine sulfate; naltrexone hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 022321-004 Aug 13, 2009 ➤ Subscribe ➤ Subscribe
Alpharma Pharms EMBEDA morphine sulfate; naltrexone hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 022321-004 Aug 13, 2009 ➤ Subscribe ➤ Subscribe
Alpharma Pharms EMBEDA morphine sulfate; naltrexone hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 022321-006 Aug 13, 2009 ➤ Subscribe ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Paragraph IV (Patent) Challenges for EMBEDA
Drugname Dosage Strength RLD Submissiondate
➤ Subscribe Extended-release Capsules 30 mg/1.2 mg, 50 mg/2 mg and 80 mg/3.2 mg ➤ Subscribe 5/28/2010
➤ Subscribe Extended-release Capsules 60 mg/2.4 mg ➤ Subscribe 5/25/2010
➤ Subscribe Extended-release Capsules 100 mg/4 mg ➤ Subscribe 5/3/2010

International Patents for EMBEDA

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

QuintilesIMS
Daiichi Sankyo
Argus Health
Deloitte
Mallinckrodt
Boehringer Ingelheim
Covington
AstraZeneca
Cerilliant

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot